secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biohaven Ltd. (BHVN)
CIK:        0001935979
Form:       8-K
Filed at:   2026-10-15T21:18:55+00:00
Accession:  0001935979-26-000080
Event type: m_and_a
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Biohaven licenses MoDE IgG degraders to Ono for $80M upfront, up to $100M near-term, ~20% royalties in Asia
--------------------------------------------------------------------------------

- Ono gets exclusive rights to develop/commercialize BHV-1300, BHV-1310, BHV-1320 in Japan, South Korea, Taiwan, and ASEAN; Biohaven retains US, Europe, China rights.
- Deal: $80M upfront at closing, $20M milestone anticipated within a year, ~20% royalties on net sales; Ono funds specified territory activities and shares global study costs.
- BHV-1300 is in Phase 3 for Graves' disease; Phase 1b showed deep reduction in TSH-receptor autoantibody, normalized free T3/T4, IgG3 sparing.
- Up to 87% total IgG reduction observed in Phase 1 studies; autoinjector self-administration; potential first-in-class extracellular IgG degrader.
- J.P. Morgan is financial advisor; Sullivan & Cromwell legal advisor. Ono ticker TYO:4528; agreement dated Oct 8, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1935979/000193597926000080/0001935979-26-000080-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1935979/000193597926000080/bhvn-20261008.htm
  HTML page:      https://secwatch.observer/filing/0001935979-26-000080

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer